Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | HTR7 | P34969 | 2/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.37 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.37 |
| ▸ | FNTA | P49354 | 3/20 | 0.36 |
| ▸ | FNTB | P49356 | 3/20 | 0.36 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3312248 | 0.96 | HDAC1 (0.44) | HDAC1HDAC6CHRM4DRD2HTR7 | |
| SCHEMBL10286472 | 0.96 | HDAC1 (0.44) | HDAC1HDAC6CHRM4DRD2HTR7 | |
| SCHEMBL2147611 | 0.90 | CHRM4 (0.41) | HDAC1HDAC6CHRM4DRD2HTR7 | |
| SCHEMBL4790662 | 0.79 | HDAC1 (0.37) | HDAC1HDAC6ADORA2AP2RX7CXCR4 | |
| SCHEMBL10286793 | 0.79 | CHRM4 (0.38) | CHRM4DRD2HTR7 | |
| SCHEMBL14768808 | 0.77 | CYP2D6 (0.41) | HDAC1HDAC6ADORA2ACXCR4CYP2D6 | |
| SCHEMBL10286869 | 0.77 | CHRM4 (0.35) | CHRM4DRD2HTR7 | |
| SCHEMBL10286808 | 0.77 | CHRM4 (0.38) | HDAC6CHRM4DRD2HTR7ADORA2A | |
| SCHEMBL31468736 | 0.76 | CXCR4 (0.36) | HDAC1HDAC6CXCR4CYP2D6 | |
| SCHEMBL30322738 | 0.76 | CXCR4 (0.36) | HDAC1HDAC6CXCR4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409589-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORP (US) | 2022-12-29 | — | — | US | disclosed |
| US-10322111-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | GENZYME CORPORATION (US) | 2019-06-18 | — | — | US | disclosed |
| EP-1465889-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORP (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20160228413-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2016-08-11 | — | — | US | disclosed |
| US-20150038509-A1 | Chemokine Receptor Binding Heterocyclic Compounds With Enhanced Efficacy | ANORMED, INC. (CA) | 2015-02-05 | — | — | US | disclosed |
| US-8778967-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | GENZYME CORPORATION (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2013-04-25 | — | — | US | disclosed |
| US-20120301427-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORPORATION | 2012-11-29 | — | — | US | disclosed |
| WO-2012001040-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-01-05 | — | — | WO | disclosed |
| EP-1465889-A4 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC (CA) | 2008-05-14 | — | — | EP | disclosed |
| US-7354934-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED, INC. (CA) | 2008-04-08 | — | — | US | disclosed |
| US-7354932-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED, INC. (CA) | 2008-04-08 | — | — | US | disclosed |
| US-20060100240-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED CORPORATION (CA) | 2006-05-11 | — | — | US | disclosed |
| EP-1628533-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004106493-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2004-12-09 | — | — | WO | disclosed |
| EP-1465889-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | AnorMED Inc. (CA) | 2004-10-13 | — | — | EP | disclosed |
| US-20040019058-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED CORPORATION (CA) | 2004-01-29 | — | — | US | disclosed |
| US-20030220341-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED, INC. (CA) | 2003-11-27 | — | — | US | disclosed |
| WO-2003055876-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220341-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | HDAC1 1094/4885HDAC6 1371/4885CHRM4 1266/4885 |
| US-10322111-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | HDAC1 1094/4885HDAC6 1371/4885CHRM4 1266/4885 |
| US-20060100240-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | HDAC1 1094/4885HDAC6 1371/4885CHRM4 1266/4885 |
| US-20150038509-A1 | Chemokine Receptor Binding Heterocyclic Compounds With Enhanced Efficacy | CCR5, CXCR4, CXCR3 | HDAC1 1094/4885HDAC6 1371/4885CHRM4 1266/4885 |
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | MSR1, DDT, MPO | HDAC1 3287/4885HDAC6 3589/4885CHRM4 299/4885 |
| US-20120301427-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | CCR5, CXCR4, CXCR3 | HDAC1 1111/4885HDAC6 1365/4885CHRM4 1473/4885 |
| US-20220409589-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | CCR5, CXCR4, CXCR3 | HDAC1 1094/4885HDAC6 1371/4885CHRM4 1266/4885 |
| US-20160228413-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | CCR5, CXCR4, CXCR3 | HDAC1 1094/4885HDAC6 1371/4885CHRM4 1266/4885 |
| US-20040019058-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | HDAC1 1094/4885HDAC6 1371/4885CHRM4 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.